34 children older than 3 months were enrolled.
Methods: After ethics committee approval, 51 patients (mean age, 14 years 7 months) were enrolled in this clinical trial.
A total of 2151 newly married couples planning to become pregnant within the next 12 months were enrolled between 2009 and 2012 from two counties of Shanxi Province in northern China.
One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1 3 attacks.
Following the exclusion of patients with no interest for participation, refused to have TEE and/or could not be age- and sex matched or had other exclusion criteria; 100 patients with migraine and 100 age- and sex-matched subjects with chronic TTH and 50 healthy volunteers with no headache in the last 6 months were enrolled in the study.
148 subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack per month in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or rizatriptan 10 mg treating 1 3 attacks.
In all, 1,235 children aged 3 59 months were enrolled.
One hundred and twenty-nine infants aged 16 months were enrolled in this prospective study.
ACT is not recommended in very young children (according to manufacturer's instructions) and, therefore, only children aged 3 59 months with caretakers who were residents for at least six months were enrolled.
209 infants (median age: 2.4 months) were enrolled in a prospective study of infants <1 year old, hospitalized for a first episode of bronchiolitis during the winter epidemic season and with no high risk for severe disease.
Adding a margin to the minimum required sample size, a cohort of 458 participants on long-term ART (range 12 to 99 months) were enrolled during March-September 2008 [19] for a cross-sectional assessment and a retrospective review of their medical charts.
